Atlas Trials

Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer

Clinical trial NCT05223088 · COMPLETED

Trial details

NCT number
NCT05223088
Sponsor
Fujian Cancer Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
ImmunotherapyGastrict Cancer
Start date
2021-10-31
Primary completion
2023-04-30
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.